Perspective Therapeutics, Inc. (NYSE:CATX) CFO Juan Graham Purchases 33,333 Shares

Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) CFO Juan Graham bought 33,333 shares of the stock in a transaction dated Friday, March 28th. The stock was bought at an average price of $2.25 per share, with a total value of $74,999.25. Following the purchase, the chief financial officer now owns 35,354 shares of the company's stock, valued at approximately $79,546.50. This represents a 1,649.33 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Perspective Therapeutics Price Performance

Shares of CATX traded down $0.16 during mid-day trading on Friday, hitting $1.80. The stock had a trading volume of 1,189,656 shares, compared to its average volume of 1,013,026. Perspective Therapeutics, Inc. has a fifty-two week low of $1.79 and a fifty-two week high of $19.05. The company's fifty day simple moving average is $2.77 and its two-hundred day simple moving average is $5.91.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on CATX shares. HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Perspective Therapeutics in a research report on Monday, March 31st. Brookline Capital Management upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a report on Monday, March 10th. Wedbush restated an "outperform" rating and set a $11.00 target price on shares of Perspective Therapeutics in a research note on Wednesday, March 26th. Scotiabank began coverage on Perspective Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $15.00 target price on the stock. Finally, Lifesci Capital raised Perspective Therapeutics to a "strong-buy" rating in a report on Thursday, March 6th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $14.44.

Hedge Funds Weigh In On Perspective Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Y Intercept Hong Kong Ltd acquired a new stake in shares of Perspective Therapeutics during the fourth quarter worth $33,000. Aigen Investment Management LP acquired a new stake in Perspective Therapeutics during the fourth quarter worth about $34,000. National Bank of Canada FI raised its stake in Perspective Therapeutics by 549,900.0% during the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock worth $35,000 after acquiring an additional 10,998 shares during the period. ProShare Advisors LLC lifted its holdings in Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock worth $49,000 after acquiring an additional 5,011 shares during the last quarter. Finally, Vontobel Holding Ltd. acquired a new position in Perspective Therapeutics in the fourth quarter valued at approximately $51,000. Institutional investors and hedge funds own 54.66% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.